Jonjones325 Tuesday, 04/09/19 08:03:18 AM Re: None Post # of 232219 Value-Creating Catalysts – Clinical updates from Phase 2 Parkinson’s disease dementia study, Phase 2b/3 Alzheimer’s disease and Phase 2 Rett syndrome studies anticipated in 2019. Clinical data publications and additional indications to be announced in 2019. So many to choose from. What could it be? Anxiety disorders, mood disorders, psychotic disorders, etc. Come on Merck, let's do this partnership for these other indications.